Anokion is harnessing the power of natural immune equilibrium to develop solutions for antigen-specific immune tolerance.
anokion has raised €73M across 2 funding rounds from 1 investor, most recently a round in Oct 2022. Based in Ecublens, Switzerland; founded 2010; active in Healthtech. Data as of 6 Aug 2026.
Timing: overdue vs cohort gap · momentum flat. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2022-10-19 | Other | €36M | Pfizer Breakthrough Growth Initiative | View deal → |
| 2019-10-01 | Series B | €37M | — | View deal → |
